Rejuvel Bio-Sciences (NUUU) Inactive 10-Q14 Aug 142014 Q2 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2014	Aug. 13, 2014
Document And Entity Information	'	'
Entity Registrant Name	'Technology Applications International Corp	'
Entity Central Index Key	'0001481427	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	118,581,119
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets	'	'
Cash and cash equivalents	$172,634	$4,891
Inventories	87,819	70,862
Deposits	7,000	7,000
Other current assets	1,909	1,909
Total current assets	269,362	84,662
Trademarks, net	1,886	1,940
Machinery and equipment, net	18,724	19,371
Total assets	289,972	105,973
Liabilities	'	'
Accounts payable and accrued expenses	353,420	344,415
Advances from affiliate	335,940	237,480
Loan from affiliate	77,401	77,401
Convertible debentures (net of debt discount of $0 and $75,902 respectively)	0	198,099
Derivative liability	668,355	349,940
Total current liabilities	1,435,116	1,207,335
Total liabilities	1,435,116	1,207,335
Shareholders' deficit	'	'
Preferred stock, par value, $0.001 per share, 50,000,000 shares authorized, none issued or outstanding	0	0
Common stock, par value $0.001 par value, 300,000,000 shares authorized, 118,581,149 and 117,348,000 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively.	118,582	117,348
Additional paid in capital	1,217,544	586,199
Subscription receivable	0	0
Accumulated deficit	-2,481,270	-1,804,909
Total shareholders' deficit	-1,145,144	-1,101,362
Total liabilities and shareholders' deficit	$289,972	$105,973

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	118,581,149	117,348,000
Common stock, shares outstanding	118,581,149	117,348,000
Discount on convertible debentures	$0	$75,902

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended		56 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Income Statement [Abstract]	'	'	'	'	'
Revenues	$43,056	$21,481	$45,324	$31,528	$106,362
Cost of revenues	5,974	1,809	8,894	7,258	40,193
Gross profit	37,082	19,672	36,430	24,270	66,169
Expenses	'	'	'	'	'
General and administrative	162,403	149,043	291,131	287,701	1,783,625
Loss From Operation	-125,321	-129,371	-254,701	-263,431	-1,717,456
Other income (expense)	'	'	'	'	'
Gain (loss) on derivative valuation	1,862,393	118,400	-64,404	93,400	77,082
Derivative expense	-15,341	0	-267,155	0	-267,155
Gain on forgiveness of debts	0	0	0	0	1,000
Interest expense	-10,319	-128,157	-90,101	-157,531	-574,687
Total other income (expense)	1,836,733	-9,757	-421,660	-64,131	-763,814
Net Income (Loss)	$1,711,412	($139,128)	($676,631)	($327,562)	($2,481,270)
Loss per share	'	'	'	'	'
Basic	$0.01	$0	($0.01)	$0	'
Diluted	$0.01	$0	($0.01)	$0	'
Weighted average number of shares	'	'	'	'	'
Basic	118,573,786	117,248,000	118,128,337	117,248,000	'
Diluted	119,795,413	117,248,000	118,128,337	117,248,000	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended		56 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Cash flows from operating activities	'	'	'
Net loss	($676,631)	($327,562)	($2,481,270)
Adjustments to reconcile net income to net cash used in operating activities:	'	'	'
Loss (Gain) on derivative valuation	64,404	-93,400	-77,082
Derivative expense	267,155	0	267,155
Gain on forgiveness of debts	0	0	-1,000
Amortization of discount on convertible debentures	75,902	147,001	522,452
Depreciation and amortization	2,519	2,040	15,031
Shares issued for services rendered	0	0	11,318
Change in current assets and current liabilities:	'	'	'
(Increase) Decrease in Inventory	-16,957	5,138	-87,819
(Increase) Decrease in Deposits	0	-10,000	-7,000
(Increase) Decrease in Other Current Assets	0	1,905	-1,909
Increase in Accounts Payable and Accrued Expenses	38,939	128,396	384,354
(Increase) Decrease in Other Current Liabilities	0	2,000	0
Net cash used in operating activities	-244,399	-144,482	-1,455,716
Cash flows from investing activities	'	'	'
Purchase of equipment	-1,818	0	-33,371
Increase in trademarks	0	0	-2,170
Net cash used in investing activities	-1,818	0	-35,541
Cash flows from financing activities	'	'	'
Proceeds from short-term advance	0	5,000	0
Advances from (to) affiliate, net	148,458	-13,438	540,069
Proceeds from loan from affiliate	0	0	125,000
Repayment of loan from affiliate	-49,998	-11,479	-149,928
Proceeds from issuance of convertible debenture	0	45,000	324,000
Proceeds from issuance of common stock	315,500	0	824,750
Net cash used in financing activities	413,960	25,083	1,663,891
Net change in cash and cash equivalents	167,743	-119,399	172,634
Cash and cash equivalents, beginning balance	4,891	120,697	0
Cash and cash equivalents, ending balance	172,634	1,298	172,634
Supplemental disclosure of cash flow information	'	'	'
Income taxes paid	0	0	0
Interest paid	0	0	0
Non-cash transactions affecting Operating, Investing and Financing activities	'	'	'
Deposit converted to convertible debenture	0	0	100,000
Issuance of common stock - shareholder note payable	0	0	101,800
Issuance of common stock for services	0	0	11,318
Issuance of common stock for convertible notes converted	$578,454	$0	$578,454

1_Nature_of_Operations_and_Bas

1. Nature of Operations and Basis of Presentation	6 Months Ended
1. Nature of Operations and Basis of Presentation	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
1. Nature of Operations and Basis of Presentation	'
	1. Nature of Operations and Basis of Presentation

	Nature of Operations

	Technology Applications International Corporation (formerly Raj Ventures, Inc.) (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Renuell Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”, a development stage company. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.

	Principles of Consolidation

	The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Renuell Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.

	Basis of Presentation and Going Concern Considerations

	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014.

	For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

	The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

	These consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies.

	Development Stage Risk

	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.

	The Company has minimal revenues generated from operations due to the sale of sample products. Accordingly, the Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”. Among the disclosures required are that the Company’s financial statements be identified as those of a development stage company and that the statements of operations, shareholders’ equity / (deficit) and cash flows disclose activity since the date of the Company’s inception.

2_Inventories

2. Inventories	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
2. Inventories	'
	2. Inventories

	Inventories are stated at the lower of cost or market value. The Company reduces the value of its inventories to market value when the value is believed to be less than the cost of the item.

		June	December
		30, 2014	31, 2013

	Raw materials	$ -	$ -
	Work-in-process	-	-
	Finished goods	87,819	70,862

	Total Inventories	$87,819	$70,862


	No reserves for inventory have been deemed necessary at June 30, 2014.

3_Machinery_and_Equipment

3. Machinery and Equipment	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
3. Machinery and Equipment	'
	3. Machinery and Equipment

	Machinery and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized. When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years. Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter.

	Machinery and equipment, as of June 30, 2014 and December 31, 2013, consisted of the following:

		Estimated Useful Lives	June	December
			30, 2014	31, 2013

	Computer Equipment	3 Years	$ 5,980	$ 4,162
	Machinery and equipment	5 Years	13,418	13,418
	Furniture and fixtures	7 Years	14,073	14,073
	Accumulated depreciation		-14,747	-12,282

			$ 18,724	$ 19,371


	Depreciation expense for the six month periods ended June, 2014 and 2013 were $2,465 and $1,986, respectively. Depreciation expense for the three month periods ended June 30, 2014 and 2013 were $1,283 and $993, respectively.

4_Convertible_Debenture

4. Convertible Debenture	6 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
4. Convertible Debenture	'
	4. Convertible Debenture

	During December 2011, the Company received $100,000 as a deposit for entering into a distribution agreement. On March 22, 2012, the Company converted the $100,000 deposit into a convertible debenture. The convertible debenture bears interest at a rate of five-percent (5%) per annum and was payable March 21, 2014. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder received warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share. In February 2014, the Noteholder elected to convert $84,143 (including accrued interest of $9,143) into 168,285 shares of the Company’s Common Stock at $0.50 per share. The Company issued 218,285 warrants to purchase a 218,285 shares of common stock exercisable at $1.00 per share. As of June 30, 2014, 218,285 warrants are not exercised or expired. Warrant expiration date is September 21, 2014 (180 days after the Company’s common stock commences quotation on the OTC Bulletin Board (March 25, 2014).

	On September 25, 2012, the Company issued a $100,000 convertible debenture. The convertible debenture bears interest at a rate of five-percent (5%) per annum and was payable September 20, 2013. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder received warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. This convertible debenture extended 360 days on September 21, 2013. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share. In February 2014, the Noteholder elected to convert $88,273 (including accrued interest of $13,273) into 176,515 shares of the Company’s Common Stock at $0.50 per share. The Company issued 226,515 warrants to purchase a 226,515 shares of common stock exercisable at $1.00 per share. As of June 30, 2014, 226,515 warrants are not exercised. Warrant expiration date is September 21, 2014 (180 days after the Company’s common stock commences quotation on the OTC Bulletin Board (March 25, 2014).

	On April 3, May 23, May 31, June 10, July 29, August 14, and September 25, 2013, the Company issued a $5,000, $10,000, $10,000, $25,000, $4,000, $50,000 and $20,000 convertible debentures, respectively. The convertible debentures bear interest at a rate of ten-percent (10%) per annum and is payable March 29, May 18, May 26, June 5, 2014, July 24, august 9, September 20, 2014, respectively. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In February 2014, the Noteholder elected to convert $110,866 (including accrued interest of $6,866) into 220,785 shares of the Company’s Common Stock at $0.50 per share. The Company issued 220,785 warrants to purchase 220,785 shares of common stock exercisable at $1.00 per share. In April 2014, the Noteholder elected to convert $21,534 (including accrued interest of $1,534) into 41,534 shares of the Company’s Common Stock at $0.50 per share. The Company issued 41,534 warrants to purchase 41,534 shares of common stock exercisable at $1.00 per share. As of June 30, 2014, 262,319 warrants are not exercised. Warrant expiration date is September 21, 2014 (180 days after the Company’s common stock commences quotation on the OTC Bulletin Board (March 25, 2014).

	The following table reflects the components of the initial allocation:

	Compound derivative	$521,452
	Convertible debentures payable, net of discount	-
	Interest expense	197,452
		$324,000


	The Compound derivative comprises certain derivative features embedded in the host convertible debenture contracts including the conversion feature and warrants both of which contain anti-dilution protections. These instruments were combined into one compound derivative and bifurcated from the host instrument at fair value. The Company applied the Black-Scholes Merton valuation technique to fair value these derivatives because this technique embodies all of the assumptions necessary to fair value these compound derivative instruments.

	Since the derivative financial instruments are required to be recorded, both initially, and subsequently, at fair value, there were insufficient proceeds to allocate any amount to the convertible debentures and, accordingly, it has no carrying value on the date of inception. Additionally, proceeds were insufficient to record the fair values of the derivative financial instruments, resulting in initial interest expense of $197,452. It should be noted that the derivative instruments will be adjusted to fair value at each reporting date. As the Company does not have historical volatility data for its own stock, the expected volatility was based upon the Company’s peer group in the industry in which it does business. Fair values are highly influenced by the trading stock price and volatility of the peer group, changes in our credit risk and market interest rates.

	The company amortizes the discount on the convertible debentures resulting from the initial allocation over the term of the convertible debt instruments using the effective method. Amortization expense arising from this method for six months and the years ended June 30, 2014 and December 31, 2013 amounted to $75,901 and $182,197 which have been included as a component of interest expense. For the six months ended June 30, 2014, loss on derivative valuation was $64,404 (For the year ended December 31, 2013, gain on the derivative valuation was $64,232)

5_Capital_Stock

5. Capital Stock	6 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
5. Capital Stock	'
	5. Capital Stock

	On October 14, 2009, the Company issued 3,000,000 shares of common stock for $3,000.

	On August 26, 2010, the Company issued 100,000 shares of its common stock to purchase equipment.

	On October 20, 2011, the Company issued 101,800,000 shares of its common stock as payment for cancellation of debt for part of the amount due to its related party.

	On October 28, 2011, the Company issued 5,727,000 shares of its common stock to a consultant as payment for services rendered.

	On November 8, 2011, the Company issued 5,591,000 shares of its common stock to a consultant as payment for services rendered.

	During November and December 2011, the Company issued 236,000 shares of its common stock through a private placement to several investors for total cash consideration of $118,000.

	During January and February 2012, the Company issued 794,000 shares of its common stock through a private placement for total cash consideration of $397,000.

	In December 31, 2013, the Company issued 100,000 shares of its common stock at $0.50 for conversion of convertible debenture of $50,000.

	In February 2014, the Company issued 565,615 shares of its common stock at $0.50 for conversion of convertible debenture of $254,000 and 28,282 of accrued interest.

	In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, Company issued 601,000 warrants to purchase to purchase 601,000 shares of common stock exercisable at $1.00 per share.

	On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 180 days after stock issuance date.

	On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 180 days after stock issuance date.

	Due to a ratchet provision, the warrants issued during the period were accounted for as a derivative and fair valued using the Black Scholes valuation model. The initial valuation was $397,402 including $267,155 of amounts that exceeded the proceeds of the common stock and were therefore expensed immediately to derivative expense.

	Stock Purchase Warrants

	In conjunction with the Private Placement Memorandum dated October 28, 2011, the Company is offering up to 10,000 Units. Each Unit consists of 1,000 shares of common stock priced at $0.50 per share and one Class A Warrant to purchase 1,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire on the earlier of (i) 180 days after the common stock commences quotation on the OTC Bulletin Board or (ii) one year after the date of issuance.

	Warrants to purchase up to1,030,000 shares of common stock were issued in accordance with the Private Placement Memorandum stated above. Of these issuances, warrants to purchase up to 236,000 shares and 794,000 shares of common stock expired during 2012 and 2013.

	In conjunction with the Private Placement Memorandum dated February 13, 2013, the Company is offering up to 3,000,000 units. Each unit consists of 1 share of common stock priced at $1.00 and one Class A Warrant to purchase 1 share of common stock with an exercise price of $1.50 per share. These warrants expire on the earlier of (i) 180 days after the common stock commences quotation on the OTC Bulletin Board or (ii) one year after the date of issuance. No issuances have been sold from this offering as of December 31, 2013.

	In December 2013, the Noteholder elected to convert $50,000 into 100,000 shares of the Company’s Common Stock at $0.50 per share. The Company issued 100,000 warrants to purchase a 100,000 shares of common stock exercisable at $1.00 per share.

	In February and April 2014, the Noteholder elected to convert $304,049 (including accrued interest of $30,049) into 607,119 shares of the Company’s Common Stock at $0.50 per share. The Company issued 607,119 warrants to purchase a 607,119 shares of common stock exercisable at $1.00 per share.

	In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, the Company issued 601,000 warrants to purchase 601,000 shares of common stock exercisable at $1.00 per share.

	On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 180 days after stock issuance date.

	On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 180 days after stock issuance date.

	The following table summarizes all warrant activity for the years ended March 31, 2014 and December 31, 2013:

		Shares	Weighted-Average Exercise Price Per Share
	Outstanding, December 31, 2013	100,000	1

	Exercisable at December 31, 2013	100,000	1
	Granted	1,233,149	1
	Expired	-100,000	1
	Outstanding, June 30, 2014	1,233,149	1

6_Fair_Value_Measurements

6. Fair Value Measurements	6 Months Ended
6. Fair Value Measurements	Jun. 30, 2014
Notes to Financial Statements	'
6. Fair Value Measurements	'
	6. Fair Value Measurements

	On a recurring basis, we measure certain financial assets and liabilities based upon the fair value hierarchy. The following table presents information about the Company’s liabilities measured at fair value as of June 30, 2014 and December 31, 2013:


		Level 1	Level 2	Level 3	Fair Value at
		Level 1	Level 2	Level 3	30-Jun-14
	Liabilities
	Derivative Liability	-	-	$ 668,335	$ 668,335


		Level 1	Level 2	Level 3	Fair Value at
		Level 1	Level 2	Level 3	31-Dec-13
	Liabilities
	Derivative Liability	-	-	$ 349,940	$ 349,940


	The fair value changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), relate solely to the derivative liability as follows:

	Balance as of December 31, 2012	$ 276,000
	Derivative liability recorded	266,912
	Adjustment due to conversion	-31,080
	Fair value adjustment	-161892
	Balance at December 31, 2013	349,940
	Adjustment due to conversion	-143,391
	New warrant issued with stock	397,402
	Fair value adjustment	64,404
	Balance at June 30, 2014	$ 668,355

7_Related_Parties

7. Related Parties	6 Months Ended
7. Related Parties	Jun. 30, 2014
Related Party Transactions [Abstract]	'
7. Related Parties	'
	7. Related Parties

	An affiliate of the Company, an entity owned by the Company’s president, has been funding operations of the Company by making payments directly to third parties or advancing monies to the Company. These amounts bear no interest and are payable on demand. Amounts due to the affiliate at June 30, 2014 and December 31, 2013 are approximately 336,000 and $237,000, respectively.

	During June 2012, the Company borrowed $125,000 from an affiliate. The loan bears interest at 10% per annum and is unsecured and payable upon demand. The Company has paid $36,120 towards the loan amount. The outstanding balance at June 30, 2014 and December 31, 2013 is $77,401.

8_Subsequent_Events

8. Subsequent Events	6 Months Ended
8. Subsequent Events	Jun. 30, 2014
Subsequent Events [Abstract]	'
8. Subsequent Events	'
	8. Subsequent Events

	Pursuant to Accounting Standards Codification 855-10, the Company has evaluated all events or transactions that have occurred from July 1, 2014 through the filing with the SEC.

	On July 25, 2014, Technology Applications International Corporation and its wholly-owned subsidiary Renuell Int’l, Inc., Florida corporations (the “Company”) entered into an exclusive License Agreement (the “License Agreement”) by and between the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) for the use of U.S. Patent No.’s 6,485,963 B1, an invention entitled “Growth Stimulation Of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof” which was filed on June 2, 2000, and U.S. Patent No. 6,673,597 B2, for an invention entitled “Growth Stimulation of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof: which was filed on February 28, 2001 (the “Patents”). We currently use the Patents process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patents as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

	In consideration of the grant of the License Agreement, the Company will pay a 3% royalty to N.A.S.A. on the gross sales of any royalty-base products. The License agreement further requires the Company to remit to N.A.S.A. a non-refundable license fee in the amount of Fifteen Thousand Dollars ($15,000) upon the execution of the License Agreement and then another Fifteen Thousand Dollars ($15,000) is due six months after the license commencement date. The Company also agrees to pay N.A.S.A. a minimum royalty of Fifteen Thousand Dollars ($15,000), at the end of each accounting period (“Accounting Period”). The Accounting Period shall begin at the end of the second Accounting period of the License Agreement and each Accounting period thereafter.

	The License Agreement requires that the Company achieve a practical application of the Patent within eighteen (18) months from the commencement date of the License Agreement. In accordance with the appendix to the License Agreement; wherein it states that by August 2014, the Company shall have tested the product to meet federal, state and international regulations of its skin cream products, by October 2014, the Company shall have packaged and filled five products and by December 2014, the Company shall have Domestic and International distribution of five products. Once a practical application is achieved the term of the agreement shall be equal to the unexpired term of the last patent to be in effect of the patent(s) encompassed under the Patents. The Company further agrees that any products using the Patents process shall be substantially manufactured in the United States.

	On July 21, 2014, the Company entered stock subscription agreement for 50,000 shares at $1.00 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 180 days after stock issuance date.

1_Nature_of_Operations_and_Sum

1. Nature of Operations and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Nature of Operations	'
	Nature of Operations

	Technology Applications International Corporation (formerly Raj Ventures, Inc.) (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Renuell Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”, a development stage company. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.

Principles of Consolidation	'
	Principles of Consolidation

	The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Renuell Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.

Basis of Presentation and Going Concern Considerations	'
	Basis of Presentation and Going Concern Considerations

	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014.

	For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

	The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

	These consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies.

Development Stage Risk	'
	Development Stage Risk

	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.

	The Company has minimal revenues generated from operations due to the sale of sample products. Accordingly, the Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”. Among the disclosures required are that the Company’s financial statements be identified as those of a development stage company and that the statements of operations, shareholders’ equity / (deficit) and cash flows disclose activity since the date of the Company’s inception.

2_Inventories_Tables

2. Inventories (Tables)	6 Months Ended
2. Inventories (Tables)	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
		June	December
		30, 2014	31, 2013

	Raw materials	$ -	$ -
	Work-in-process	-	-
	Finished goods	87,819	70,862

	Total Inventories	$87,819	$70,862

3_Machinery_and_Equipment_Tabl

3. Machinery and Equipment (Tables)	6 Months Ended
3. Machinery and Equipment (Tables)	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Machinery and equipment	'
		Estimated Useful Lives	June	December
		Estimated Useful Lives	30, 2014	31, 2013

	Computer Equipment	3 Years	$ 5,980	$ 4,162
	Machinery and equipment	5 Years	13,418	13,418
	Furniture and fixtures	7 Years	14,073	14,073
	Accumulated depreciation		-14,747	-12,282

			$ 18,724	$ 19,371

4_Convertible_Debenture_Tables

4. Convertible Debenture (Tables)	6 Months Ended
	Jun. 30, 2014
Notes to Financial Statements	'
Fair value of the warrants granted utilizing	'
	Compound derivative	$521,452
	Convertible debentures payable, net of discount	-
	Interest expense	197,452
		$324,000

5_Capital_Stock_Tables

5. Capital Stock (Tables)	6 Months Ended
5. Capital Stock (Tables)	Jun. 30, 2014
Notes to Financial Statements	'
Warrant Activity	'
		Shares	Weighted-Average Exercise Price Per Share
	Outstanding, December 31, 2013	100,000	1

	Exercisable at December 31, 2013	100,000	1
	Granted	1,233,149	1
	Expired	-100,000	1
	Outstanding, June 30, 2014	1,233,149	1

6_Fair_Value_Measurements_Tabl

6. Fair Value Measurements (Tables)	6 Months Ended
6. Fair Value Measurements (Tables)	Jun. 30, 2014
Notes to Financial Statements	'
Derivative Liabilities	'

		Level 1	Level 2	Level 3	Fair Value at
		Level 1	Level 2	Level 3	30-Jun-14
	Liabilities
	Derivative Liability	-	-	$668,335	$668,335

		Level 1	Level 2	Level 3	Fair Value at
		Level 1	Level 2	Level 3	31-Dec-13
	Liabilities
	Derivative Liability	-	-	$349,940	$349,940

Derivative Liability Fair Value Adjustment	'
	Balance as of December 31, 2012	$ 276,000
	Derivative liability recorded	266,912
	Adjustment due to conversion	-31,080
	Fair value adjustment	-161892
	Balance at December 31, 2013	349,940
	Adjustment due to conversion	-143,391
	New warrant issued with stock	397,402
	Fair value adjustment	64,404
	Balance at June 30, 2014	$ 668,355

2_Inventories_Details

2. Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]	'	'
Raw materials	$0	$0
Work-in-process	0	0
Finished goods	87,819	70,862
Total Inventories	$87,819	$70,862

3_Machinery_and_Equipment_Deta

3. Machinery and Equipment (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
3. Machinery and Equipment (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Computer Equipment	Machinery and Equipment	Furniture and Fixtures
Computer Equipment	$5,980	$4,162	'	'	'
Machinery and equipment	13,418	13,418	'	'	'
Furniture and fixtures	14,073	14,073	'	'	'
Accumulated depreciation	-14,747	-12,282	'	'	'
Machinery and equipment, net	$18,724	$19,371	'	'	'
Estimated useful lives	'	'	'3 years	'5 years	'7 years

3_Machinery_and_Equipment_Deta1

3. Machinery and Equipment (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
3. Machinery and Equipment (Details Narrative) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation expense	$1,238	$993	$2,465	$1,986

4_Convertible_Debenture_Detail

4. Convertible Debenture (Details) (USD $)	6 Months Ended		12 Months Ended	56 Months Ended
4. Convertible Debenture (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014
Notes to Financial Statements	'	'	'	'
Compound derivative	$267,155	$0	$521,452	$267,155
Convertible debentures payable, net of discount	'	'	0	'
Interest expense	'	'	197,452	'
Total convertible debentures	'	'	$324,000	'

4_Convertible_Debenture_Detail1

4. Convertible Debenture (Details Narrative) (USD $)

1 Months Ended

2 Months Ended

6 Months Ended

12 Months Ended

56 Months Ended

Apr. 30, 2014

Feb. 28, 2014

Dec. 31, 2013

Dec. 31, 2011

Feb. 29, 2012

Dec. 31, 2011

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jul. 21, 2014

Apr. 16, 2014

Apr. 03, 2014

Sep. 25, 2013

Aug. 14, 2013

Jul. 29, 2013

Jun. 10, 2013

31-May-13

23-May-13

Apr. 03, 2013

Sep. 25, 2012

Mar. 22, 2012

Notes to Financial Statements

Deposit on distribution agreeement

$100,000

Deposit converted into convertible debenture

100,000

Convertible debenture issued

20,000

50,000

4,000

25,000

10,000

5,000

100,000

Interest rate of convertible debenture, per annum

10.00%

0.00%

5.00%

Maturity date of convertible debenture

'1 year

Debt conversion to common stock rate

$0.50

Number of warrants offered per share issued from converted debt

Warrants exercisable for common stock, price per share

Expiration of warrants, years

'1 year

Expiration of warrants, days after common stock is quoted on OTCBB

'180 days

Initial Interest expense

197,452

Amortization expense

75,902

147,001

182,197

522,452

Loss on derivative valuation

64,404

-161,892

Amount of debt converted from debentures

254,000

Shares of common stock issued from conversion of debentures

485,000

Amount of convertible debentures still outstanding

19,999

Debt discount on convertible debt

9,611

Net convertible debt

10,388

Amount of debt converted from 2013 debentures

20,767

110,866

Shares of common stock issued from conversion of 2013 debentures

41,543

220,785

Price per share of common stock converted from 2013 debentures

$0.50

Warrants issued for 2013 debentures

41,534

220,785

Exercise price of warrants issued for 2013 debentures

Expiration period of warrants issued for 2013 debentures

21-Sep-14

Warrants outstanding of the 2013 debenture warrants

262,319

Amount of 2013 convertible debentures still outstanding

21,025

Amount of debt converted from December 2011 debenture

84,143

25,000

Shares of common stock issued from conversion of December 2011 debenture

168,285

50,000

Price per share of common stock converted from December 2011 debenture

$0.50

Amount of debt converted from September 2012 debenture

$88,273

$25,000

Shares of common stock issued from conversion of September 2012 debenture

176,515

50,000

Price per share of common stock converted from September 2012 debenture

$0.50

Warrants issued for December 2011 debenture

218,285

Exercise price of warrants issued for December 2011 debenture

Expiration date of warrants issued for December 2011 debenture

21-Sep-14

Warrants outstanding of the December 2011 debenture warrants

218,285

Warrants issued for September 2012 debenture

226,515

Exercise price of warrants issued for September 2012 debenture

Expiration date of warrants issued for September 2012 debenture

21-Sep-14

Warrants outstanding of the September 2012 debenture warrants

226,515

5_Capital_Stock_Details

5. Capital Stock (Details) (USD $)	1 Months Ended	24 Months Ended				6 Months Ended
	Mar. 31, 2014	Dec. 31, 2012	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014
	Mar. 31, 2014	Dec. 31, 2012	Exercisable	Outstanding	Outstanding	Granted	Expired
Number of Warrant Shares, instant	'	'	100,000	1,233,149	100,000	'	'
Number of Warrant Shares, duration	601,000	1,030,000	'	'	'	1,233,149	-100,000
Weighted Average Exercise Price, instant	'	'	$1	$0	$1	'	'
Weighted Average Exercise Price, duration	'	'	'	'	'	$1	'

5_Capital_Stock_Details_Narrat

5. Capital Stock (Details Narrative) (USD $)

1 Months Ended

2 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

24 Months Ended

Apr. 30, 2014

Mar. 31, 2014

Feb. 28, 2014

Dec. 31, 2013

Feb. 29, 2012

Dec. 31, 2011

Apr. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Jul. 21, 2014

Apr. 16, 2014

Apr. 03, 2014

Sep. 25, 2013

Aug. 14, 2013

Jul. 29, 2013

Jun. 10, 2013

31-May-13

23-May-13

Apr. 03, 2013

Feb. 13, 2013

Sep. 25, 2012

Mar. 22, 2012

Nov. 08, 2011

Oct. 28, 2011

Oct. 20, 2011

Aug. 26, 2010

Oct. 13, 2009

Units

Notes to Financial Statements

Common stock issued for cash, shares

50,000

20,000

5,000

3,000,000

Common stock issued for cash, value

$10,000

$5,000

$3,000

Common stock issued for cash, shares, duration

601,000

794,000

236,000

Common stock issued for cash, value, duration

300,500

397,000

118,000

Common stock issued for equipment, shares

100,000

Common stock issued for debt, shares

101,800,000

Common stock issued for services, shares

5,591,000

5,727,000

Private placement units offered

3,000,000

10,000

Shares per unit

1,000

Common stock price per share

$0.50

Warrants per unit

Class A Warrants, shares per warrant

1,000

Exercise price per share in warrant

$1.50

Expiration of warrants, years

'1 year

Expiration of warrants, days after common stock is quoted on OTCBB

'180 days

Number of untis sold in February 13, 2013 private offering

Number of warrant shares issued, shares

601,000

1,030,000

Number of warrant shares expired, shares

1,030,000

Common stock issued for debt, shares, duration

565,615

100,000

607,119

Common stock issued for debt, amount, duration

254,000

50,000

304,049

Common stock issued for debt, price per share

$0.50

Common stock issued for accrued interest on debt, amount, duration

28,282

Common stock issued for cash, price per share

$0.50

Warrants issued for debenture conversion

485,000

607,119

Exercise price of warrants issued for debenture conversion

Subscription receivable

66,500

Exercise price of warrants issued for stock purchase, duration

Warrant expiration period

'180 days

Valuation of warrants issued

397,402

Amount of initial warrant valuation that exceeded the proceeds of the common sotck and were expenses to derivative expense

267,155

Warrants included in stock issuance

50,000

20,000

5,000

Shares underlying warrants in stock issuance

50,000

20,000

5,000

Exercise price of warrants in stock issuance

Warrants issued for March/April 2014 debenture

226,515

Exercise price of warrants issued for March/April 2014 debenture

Amount of debt converted from debentures

$254,000

Shares of common stock issued from conversion of debentures

485,000

6_Derivative_Liabilities_Detai

6. Derivative Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Derivative liability	$668,355	$349,940	$276,000
Level 1	'	'	'
Derivative liability	0	0	'
Level 2	'	'	'
Derivative liability	0	0	'
Level 3	'	'	'
Derivative liability	668,355	349,940	'
Fair Value	'	'	'
Derivative liability	$668,355	$349,940	'

6_Derivative_Liability_Fair_Va

6. Derivative Liability Fair Value Adjustment (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Notes to Financial Statements	'	'	'
Derivative liability	$668,355	$349,940	$276,000
Derivative liability recorded	'	266,912	'
Fair value adjustment	64,404	-161,892	'
Adjustment due to conversion	-143,391	-31,080	'
New warrant issued with stock	$397,402	'	'

7_Related_Parties_Details_Narr

7. Related Parties (Details Narrative) (USD $)	1 Months Ended
7. Related Parties (Details Narrative) (USD $)	Jun. 30, 2012	Jun. 30, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]	'	'	'
Due to affiliates	'	$336,000	$237,000
Loan from affiliate	125,000	'	'
Interest rate on loan from affiliate	10.00%	'	'
Oustanding balance on loan from affiliate	'	$77,401	$77,401

8_Subsequent_Events_Details_Na

8. Subsequent Events (Details Narrative) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

Feb. 28, 2014

Jun. 30, 2014

Jul. 25, 2014

Jul. 21, 2014

Apr. 16, 2014

Apr. 03, 2014

Sep. 25, 2013

Aug. 14, 2013

Jul. 29, 2013

Jun. 10, 2013

31-May-13

23-May-13

Apr. 03, 2013

Feb. 13, 2013

Sep. 25, 2012

Mar. 22, 2012

Oct. 28, 2011

Oct. 13, 2009

Patents

Products

Subsequent Events [Abstract]

Royalty percent paid to NASA for use of two patent in exclusive License Agreement

3.00%

Number of patents included in exclusive License Agreement with NASA

Non-refundable license fee paid to NASA upon execution of License Agreement

$15,000

Second License Agreement fee due to NASA

15,000

Due date of second license fee due to NASA

'6 months

Minimum annual royalty due to NASA for License Agreement

15,000

Required time period to reach practical application of patents with License Agreement

'18 months

Required number of products required to be filled, packaged, and have distribution by December 2014

Common stock issued for cash, shares

50,000

20,000

5,000

3,000,000

Common stock issued for cash, value

10,000

5,000

3,000

Common stock issued for cash, price per share

$0.50

Warrants included in stock issuance

50,000

20,000

5,000

Shares underlying warrants in stock issuance

50,000

20,000

5,000

Exercise price of warrants in stock issuance

Warrants issued for March/April 2014 debenture

226,515

Exercise price of warrants issued for March/April 2014 debenture

Amount of debt converted from debentures

$254,000

Shares of common stock issued from conversion of debentures

485,000